CURDULATINIB
Total Payments
$2.4M
Transactions
173
Doctors
4
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $2.4M | 160 | 0 |
| 2018 | $59,841 | 13 | 4 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.4M | 160 | 97.5% |
| Consulting Fee | $57,450 | 9 | 2.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,135 | 1 | 0.1% |
| Travel and Lodging | $233.10 | 1 | 0.0% |
| Food and Beverage | $23.06 | 2 | 0.0% |
Payments by Type
Research
$2.4M
160 transactions
General
$59,841
13 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| 13-601 | PORTOLA PHARMACEUTICALS, INC. | $2.4M | 0 |
Top Doctors Receiving Payments for CURDULATINIB
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $2.4M
- Total Doctors 4
- Transactions 173
About CURDULATINIB
CURDULATINIB is a drug associated with $2.4M in payments to 4 healthcare providers, recorded across 173 transactions in the CMS Open Payments database. The primary manufacturer is PORTOLA PHARMACEUTICALS, INC..
Payment data is available from 2018 to 2019. In 2019, $2.4M was paid across 160 transactions to 0 doctors.
The most common payment nature for CURDULATINIB is "Unspecified" ($2.4M, 97.5% of total).
CURDULATINIB is associated with 1 research study, including "13-601" ($2.4M).